Journal
SMALL
Volume 18, Issue 34, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202202462
Keywords
cancer vaccine; cellular immunity; immunogenic cell death; immunotherapy; nanoadjuvant
Categories
Funding
- National Natural Science Foundation of China [NSFC 51720105015, 51929201, 51922097, 51772124, 51872282, 52102354, 52102180]
- Postdoctoral Innovative Talents Support Program [BX2021360]
- China Postdoctoral Science Foundation [2021M703130, 2021M691919]
- Science and Technology Development Planning Project of Jilin Province [20210402046GH]
Ask authors/readers for more resources
A new type of nanoadjuvant SiAl was synthesized in this study, which can significantly enhance immune response in therapeutic cancer vaccines and has potential for breast cancer treatment.
In spite of the widespread application of vaccine adjuvants in various preventive vaccines at present, the existing adjuvants are still hindered by weak cellular immunity responses in therapeutic cancer vaccines. Herein, a hollow silica nanoadjuvant containing aluminum hydroxide spikes on the surface (SiAl) is synthesized for the co-loading of chemotherapeutic drug doxorubicin (Dox) and tumor fragment (TF) as tumor antigens (SiAl@Dox@TF). The obtained nanovaccines show significantly elevated anti-tumor immunity responses thanks to silica and aluminum-based composite nanoadjuvant-mediated tumor antigen release and Dox-induced immunogenic cell death (ICD). In addition, the highest frequencies of dendritic cells (DCs), CD4(+) T cells, CD8(+) T cells, and memory T cells as well as the best mice breast cancer (4T1) tumor growth inhibitory are also observed in SiAl@Dox@TF group, indicating favorable potential of SiAl nanoadjuvants for further applications. This work is believed to provide inspiration for the design of new-style nanoadjuvants and adjuvant-based cancer vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available